Regeneron’s Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.
Daiichi Sankyo postpones annual results, stock dips
Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended



